Omnicell, Inc. (OMCL)

NASDAQ: OMCL · IEX Real-Time Price · USD
109.18
+1.85 (1.72%)
Aug 11, 2022 4:00 PM EDT - Market closed
1.72%
Market Cap 4.84B
Revenue (ttm) 1.26B
Net Income (ttm) 60.58M
Shares Out 44.29M
EPS (ttm) 1.20
PE Ratio 90.98
Forward PE 29.50
Dividend n/a
Ex-Dividend Date n/a
Volume 575,451
Open 107.80
Previous Close 107.33
Day's Range 107.50 - 112.88
52-Week Range 103.62 - 187.29
Beta 1.04
Analysts Buy
Price Target 160.78 (+47.3%)
Earnings Date Aug 4, 2022

About OMCL

Omnicell, Inc., together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; Omnicell Interface Software... [Read more...]

Industry Health Care Technology
IPO Date Aug 7, 2001
CEO Randall Lipps
Employees 4,000
Stock Exchange NASDAQ
Ticker Symbol OMCL
Full Company Profile

Financial Performance

In 2021, Omnicell's revenue was $1.13 billion, an increase of 26.88% compared to the previous year's $892.21 million. Earnings were $77.85 million, an increase of 141.81%.

Financial Statements

Analyst Forecast

According to 15 analysts, the average rating for OMCL stock is "Buy." The 12-month stock price forecast is 160.78, which is an increase of 47.26% from the latest price.

Price Target
$160.78
(47.26% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Omnicell (OMCL) Q2 Earnings Miss Estimates, Gross Margin Down

Robust sales contribution from product and services segments drove Omnicell's (OMCL) Q2 top line.

MDRX vs. OMCL: Which Stock Should Value Investors Buy Now?

MDRX vs. OMCL: Which Stock Is the Better Value Option?

Other symbols: MDRX

Omnicell (OMCL) Misses Q2 Earnings and Revenue Estimates

Omnicell (OMCL) delivered earnings and revenue surprises of -1.18% and 2.37%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Omnicell Announces Financial Results for Second Quarter 2022

SANTA CLARA, Calif.--(BUSINESS WIRE)--Omnicell Announces Financial Results for Second Quarter 2022

Analysts Estimate Omnicell (OMCL) to Report a Decline in Earnings: What to Look Out for

Omnicell (OMCL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Omnicell to Release Second Quarter 2022 Financial Results on August 4, 2022

MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--Omnicell to Release Second Quarter 2022 Financial Results on August 4, 2022

Omnicell (OMCL) Up 10% Since Q1 Earnings: What's Driving It?

Investors are optimistic about Omnicell's (OMCL) strategic partnerships and continued innovations for the Autonomous Pharmacy.

ENOV vs. OMCL: Which Stock Should Value Investors Buy Now?

ENOV vs. OMCL: Which Stock Is the Better Value Option?

Other symbols: ENOV

3 Medical Info System Stocks Braving Industry Headwinds

Medical Info Systems stocks like Omnicell, Inc. (OMCL), Axonics, Inc. (AXNX) and Outset Medical, Inc. (OM) are expected to gain despite pandemic-led disruptions.

Other symbols: AXNXOM

CPSI vs. OMCL: Which Stock Is the Better Value Option?

CPSI vs. OMCL: Which Stock Is the Better Value Option?

Other symbols: CPSI

Here's Why Investors Should Retain Omnicell (OMCL) Stock Now

Investors are optimistic about Omnicell's (OMCL) better-than-expected results and new launches.

CPSI vs. OMCL: Which Stock Should Value Investors Buy Now?

CPSI vs. OMCL: Which Stock Is the Better Value Option?

Other symbols: CPSI

Omnicell (OMCL) Q1 Earnings Top Estimates, Margins Decline

Robust sales performance across Omnicell's (OMCL) operating segments has contributed to the first-quarter top line.

Omnicell (OMCL) Q1 Earnings and Revenues Beat Estimates

Omnicell (OMCL) delivered earnings and revenue surprises of 16.90% and 0.70%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Omnicell Announces Financial Results for First Quarter 2022

MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--Omnicell Announces Financial Results for First Quarter 2022

CPSI or OMCL: Which Is the Better Value Stock Right Now?

CPSI vs. OMCL: Which Stock Is the Better Value Option?

Other symbols: CPSI

3 Healthcare Stocks to Buy and Hold for the Next 10 Years

These companies have a history of creating shareholder value -- and still have plenty of room for growth.

Other symbols: KIDSPEN

Omnicell to Release First Quarter 2022 Financial Results on April 28, 2022

MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--Omnicell to Release First Quarter 2022 Financial Results on April 28, 2022

Omnicell (OMCL) Progresses With Intelligent Infrastructure Tools

Omnicell's (OMCL) IVX Station robotic compounding technology apparently supports three times the throughput speed of the current IV robotic technology.

Omnicell Unveils Innovative IVX Station Robotic Compounding Technology in Winter 2022 Release

MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--Omnicell, Inc. (Nasdaq: OMCL), a leading provider of medication management and adherence tools for health systems and pharmacies, today announced the launch of IV...

Omnicell (OMCL) Down 5.6% Since Last Earnings Report: Can It Rebound?

Omnicell (OMCL) reported earnings 30 days ago. What's next for the stock?

Omnicell Announces Changes to Its Board of Directors

MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--Omnicell Announces Changes to its Board of Directors

CHNG vs. OMCL: Which Stock Is the Better Value Option?

CHNG vs. OMCL: Which Stock Is the Better Value Option?

Other symbols: CHNG

Omnicell (OMCL) Q4 Earnings Miss Estimates, Revenues Beat

Robust performance by the Product and Service segments is driving Omnicell's (OMCL) fourth-quarter top line.

Omnicell (OMCL) Lags Q4 Earnings Estimates

Omnicell (OMCL) delivered earnings and revenue surprises of -3.16% and 0.30%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?